

SUPPLEMENTARY TABLE 2: OTHER AGENTS. The interventions are listed by class. The setting of each study, whether hospital or outpatient, the type of control (AC: Active control, RCT: randomized control; soc: standard of care; PLAC: placebo control, whether treatment (TREAT) or prevention (PREV), the severity of illness, number of subjects, quarter study initiated, quarter study projects completion of enrollment, and duration of symptoms for patient inclusion are listed. Studies projecting completion of enrollment by the end of the second quarter of 2020 are bolded. Outpatient studies with planned completion by the end of the second quarter of 2020 are italicized.

TREATMENT	TYPE OF CONTROL	TREAT OR PREVENT	SEVERITY	NUMBER SUBJECTS	BEGIN DATE	PROPOSED END ENROLLMENT	DURATION SYMPTOMS
<b>IMMUNE GLOBULIN</b>							
CONVALESCENT PLASMA	RCT PLAC	TREAT	MIXED	500	Q2(20)	Q2(21)	14
	RCT (soc)	TREAT	MIXED	426	Q2(20)	Q3 (20)	4
	RCT (soc)	TREAT	MIXED	278	Q2(20)	Q3 (20)	12
	RCT (soc)	TREAT	SEV	200	Q1(20)	Q1(21)	3
	RCT (soc)	TREAT	SEV,CRIT	100	Q1(20)	<b>Q2(20)</b>	ANY DUR
IVIG	RCT (PLAC)	TREAT	SEV,CRIT	138	Q2(20)	Q3 (20)	ANY DUR
<b>CELL THERAPY</b>							
STEM CELL	RCT(PLAC)	PREV	HEALTHY	100	Q2(20)	Q4(20)	N/A
	Case control	TREAT	MIXED	200	Q1(20)	Q4(21)	ANY DUR
	RCT(PLAC)	TREAT	SEV	120	Q1(20)	Q2(20)	ANY DUR
<b>CARDIOVASCULAR</b>							
DISCONTINUATION OF RAS	AC (continue or discontinue RAS)	TREAT(2) PREV(1)	MIXED, HEALTHY	554;500;241 4	Q2(20),Q1(20)	Q3 (20);Q4(20);Q1(21)	ANY DUR, N/A
LOSARTAN	RCT (soc)	TREAT	MIXED	100	COMPLETE D		
	RCT (soc)	TREAT	MILD,MOD	200	Q2(20)	Q3 (20)	ANY DUR
	RCT (soc)	TREAT	MILD,MOD	580	Q2(20)	Q2(21)	3
	RCT (soc)	TREAT	SEV,CRIT	200	Q2(20)	Q2(21)	ANY DUR
TELMISARTAN	RCT(soc)	TREAT	MIXED	400	Q2(20)	Q3 (20)	ANY DUR
VALSARTAN	RCT (PLAC)	TREAT	MOD	651	Q2(20)	Q3 (20)	1

AMIODARONE	AC(verapamil)	TREAT	MIXED	804	Q2(20)	Q1(21)	ANY DUR
<b>PULMONARY TREATMENT</b>							
PIRFENIDONE	RCT (soc)	TREAT	MIXED	294	Q1(20)	<b>Q2(20)</b>	7
	RCT (soc)	TREAT	SEV,CRIT	292	Q1(20)	Q3(20)	14
HYPERBARIC OXYGEN	RCT (soc)	TREAT	MIXED	100	Q2(20)	Q2(21)	ANY DUR
INHALED NITRIC OXIDE	RCT(soc)	TREAT	MIXED	240	Q1(20)	Q2(21)	ANY DUR
	RCT(soc)	TREAT	SEV,CRIT	200	Q1(20)	Q2(21)	ANY DUR
DORNASE ALFA (cystic fibrosis agent)	RCT (soc)	TREAT	CRIT	100	Q2(20)	Q4(20)	ANY DUR
PRONE POSITION	AC(supine)	TREAT(2)	CRIT; MIXED	248;300	Q2(20)	Q4(20); Q1(21)	ANY DUR
OZONE	RCT (soc)	TREAT	MIXED	180	Q1(20)	<b>Q2 (20)</b>	7
OXYGEN/HYDROGEN	AC (oxygen)	TREAT(2)	MOD,SEV	100;440	Q1(20)	Q3 (20)	ANY DUR
SURGICAL FACE MASK	AC(face mask or none)	PREV	HEALTHY	6000	Q2(20)	Q3 (20)	N/A
CLOSED LOOP OXYGEN	AC (normal O2 delivery vs closed loop)	TREAT	MOD,SEV	216	Q2(20)	Q4(20)	ANY DUR
RESPIRATORY COACHING	RCT (soc)	TREAT	MILD,MOD	270	Q1(20)	Q3 (20)	ANY DUR
<b>ONCOLOGIC AGENTS</b>							
IMATINIB	RCT (PLAC)	TREAT(2)	SEV	304;386	Q1(20)	<b>Q2 (20)</b>	ANY DUR
LY3127804	RCT (PLAC)	TREAT	MIXED	200	Q2(20)	Q3 (20)	ANY DUR
BEVACIZUMAB	RCT (soc)	TREAT	SEV,CRIT	140	Q1(20)	<b>Q2(20)</b>	ANY DUR

**METABOLIC AGENTS**

METFORMIN	RCT (soc)	TREAT	MIXED	200	Q1(20)	<b>Q2 (20)</b>	ANY DUR
DAPLIGLIFLOZIN	RCT (PLAC)	TREAT	MILD,MOD	900	Q2(20)	Q4(20)	3
ESTRADIOL	RCT (soc)	TREAT	MILD,MOD	110	Q2(20)	Q4(20)	7
ATORVASTATIN	RCT (soc)	TREAT	MIXED	100	Q2(20)	NO DATE	ANY DUR
MEDIUM CHAIN TG	RCT (soc)	TREAT	MILD	120	Q2(20)	<i>Q2 (20)</i>	ANY DUR

#### SUPPLEMENTS

ECHINACEA AND GINGER	RCT (soc)	TREAT	MILD	100	Q2(20)	<b>Q2 (20)</b>	ANY DUR
VITAMIN D	AC (200,000 IU vs 50,000 IU), RCT(soc)	TREAT(3)	MILD,MOD	260;260;540	Q2(20)	Q3 (20), Q4(20)	3, ANY DUR
ASCORBIC ACID	RCT (PLAC)	TREAT	CRIT	140	Q1(20)	Q3 (20)	ANY DUR
ASCORBIC ACID, ZINC	AC(ascorbic acid, zinc, soc)	TREAT	MILD	520	Q2(20)	Q3 (20)	ANY DUR
LIPOIC ACID	RCT (soc)	TREAT	MIXED	394	Q1(20)	<b>Q2 (20)</b>	ANY DUR
PROBIOTICS	RCT (soc);RCT(PLAC)	TREAT;PREV	MIXED;HEALTHY	300;314	Q1(20);Q2(20)	Q3 (20)	ANY DUR
NATURAL HONEY	RCT (soc)	TREAT	MIXED	1000	Q1(20)	Q4(20)	ANY DUR
ESCIN	RCT (soc)	TREAT	MIXED	120	Q1(20)	<b>Q2 (20)</b>	ANY DUR
Crostop/Croguard	RCT (soc)	TREAT	MIXED	150	Q1(20)	<b>Q2 (20)</b>	ANY DUR
VITAMIN A	RCT (soc)	TREAT	MIXED	140	Q2(20)	NO DATE	ANY DUR

#### NEUROGENIC

TRADIPITANT	RCT (PLAC)	TREAT	SEV,CRIT	300	Q2(20)	Q3 (20)	ANY DUR
-------------	------------	-------	----------	-----	--------	---------	---------

PYRIDOSTIGMINE	RCT (PLAC)	TREAT	SEV	436	Q2(20)	Q2(21)	ANY DUR
VAZEGEPANT	RCT (PLAC)	TREAT	SEV	120	Q2(20)	Q3 (20)	ANY DUR
<b>PSYCHOLOGICAL</b>							
FLUVOXAMINE	RCT (PLAC)	TREAT	MILD	152	Q2(20)	Q3 (20)	ANY DUR
PSYCHOLOGICAL THERAPY	RCT (soc)	TREAT	MIXED	180	Q1(20)	Q1(22)	ANY DUR
<b>GLUCOCORTICOIDS</b>							
METHYLPREDNISOLONE	AC (high vs low dose)	TREAT	SEV	100	Q1(20)	Q2 (20)	ANY DUR
CORTICOSTEROID	AC (early vs late vs no steroid)	TREAT	MIXED	200	Q1(20)	Q2 (20)	ANY DUR
DEXAMETHASONE	RCT (soc)	TREAT(2)	CRIT	290;200	Q2(20)	Q3 (20),Q4(20)	1,ANY DUR
CICLESONIDE	RCT (PLAC)	TREAT	SEV	120	Q2(20)	Q3 (20)	ANY DUR
SYMBICORT	RCT (soc)	TREAT	MIXED	436	Q2(20)	Q3 (20)	2
<b>ANTICOAGULATION</b>							
ASPIRIN	RCT (soc)	TREAT	MIXED	128	Q1(20)	Q2 (20)	ANY DUR
LOW MOLECULAR WEIGHT HEPARIN	AC(lmw vs mechanical VTE prev)	PREV	MIXED	120	Q1(20)	Q2 (20)	ANY DUR
DEFIBROTIDE	RCT (PLAC)	TREAT	SEV,CRIT	120	Q2(20)	Q3 (20)	ANY DUR
ULINASTATIN	RCT (soc)	TREAT	MIXED	100	Q1(20)	Q2 (20)	ANY DUR

